Skip to main content
SpringerLink
Log in

Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Previously we have demonstrated that the in vitro generation of P815-specific anti-tumor cytotoxic T lymphocytes (CTL) was suppressed by splenic suppressor T cells from late tumor-bearing hosts (TBH). Suppression is not caused by in vitro growth of P815 from splenic metastases, since suppression was also seen with spleen cells from late TBH mice bearing a hypoxanthine/aminopterin/thymidine-sensitive subline (PHS-5) of P815 in the presence of HAT. Cyclophosphamide has been shown to inhibit theinduction of suppressor cells selectively in a number of immune responses, but evidence that it can inhibit active tumor-induced suppressor T cells is limited. We have found that suppressor T cells already induced by P815 in syngeneic late TBH are sensitive to low doses of cyclophosphamide (50 mg/kg) given 1 day before spleen harvest, but the in vitro CTL response of late TBH spleen cells could not be restored by pretreating the mice with cyclophosphamide, even when exogenous interleukin-2 was added to the cultures. Although 50 mg/kg cyclophosphamide did not inhibit the CTL response of spleen cells from mice immunized with P815 +Corynebacterium parvum, the same dose of cyclophosphamide eliminated the CTL response of spleen cells from early TBH. Interleukin-2 (IL-2) did not overcome this effect of cyclophosphamide, suggesting a direct effect on CTL. “Ultra-low”-dose cyclophosphamide (10 mg/kg) did not adversely effect early TBH CTL but was still able to eliminate suppressor T cell activity from late TBH. Nevertheless, late TBH CTL remained unresponsive after pretreatment of mice with ultra-low-dose cyclophosphamide, even when exogenous IL-2 was added in vitro. CTL precursor frequency analyses demonstrated that cyclophosphamide pretreatment had little or no effect on the numbers of CTL precursors from early TBH. Late TBH CTL precursor cells were not detectable in these studies, with or without suppressor T cell inhibition by cyclophosphamide pretreatment. Thus, it appears that most CTL precursor cells may be lost or irretrievably inactivated in the spleens of late TBH mice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Askenase PW, Hayden BJ, Gershon RK (1975) Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 141: 697

    Google Scholar 

  2. Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65: 87

    Google Scholar 

  3. Bear HD (1986) Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T cells from immune and early tumorbearing host spleens. Cancer Res 46: 1805

    Google Scholar 

  4. Bear HD (1987) Production of tumor-specific suppressor T cell hybridomas. J Surg Res 42: 369

    Google Scholar 

  5. Bear HD, Susskind BM, Close KA, Barrett SK (1988) Phenotype of syngeneic tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens. Cancer Res 48: 1422

    Google Scholar 

  6. Berd D, Maguire HC Jr, Mastrangelo MJ (1986) Induction of cellmediated immunity to autologous melanoma cells and regression of metastases after treatment with melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572

    Google Scholar 

  7. Berd D, Maguire HC Jr, Mastrangelo MJ (1984) Impairment of Concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res 44: 1275

    Google Scholar 

  8. Boyer CM, Kreider JW, Bartlett GL (1982) Regulation of the expression of adoptive tumor rejection immunity by recipient cyclophosphamide-sensitive cells. Cancer Res 42: 2211

    Google Scholar 

  9. Cozzolino F, Torcia M, Carossino AM, Giordani R, Selli C, Talini G, Reali E, Novelli A, Pistoia V, Ferrarini M (1987) Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response. J Exp Med 166: 303

    Google Scholar 

  10. Dye ES, North RJ (1984) Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression. Transplantation 37: 600

    Google Scholar 

  11. Ferguson RM, Simmons RL (1978) Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors. Transplantation 25: 36

    Google Scholar 

  12. Gillis S, Fern MM, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a qualitative microassay for activity. J Immunol 120: 2027

    Google Scholar 

  13. Greenberg PD, Kern DE, Cheever MA (1985) Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2− T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161: 1122

    Google Scholar 

  14. Hancock EJ, Kilburn DG (1982) The effects of cyclophosphamide on in vitro cytotoxic responses to syngeneic tumor. Cancer Immunol Immunother 14: 54–58

    Google Scholar 

  15. Hengst JCD, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41: 2163

    Google Scholar 

  16. Hurme M (1979) Differential cyclophosphamide sensitivity of precursor cells in allogeneic and H-2 restricted cytotoxic responses. J Exp Med 149: 290

    Google Scholar 

  17. Johnson TR, North RJ (1987) Frequency analysis of augmented CTL production associated with Corynebacterium parvum-induced tumor regression. Immunology 60: 361

    Google Scholar 

  18. Kaufmann SHE, Hahn H, Diamanstein T (1980) Relative susceptibilities of T cell subsets involved in delayed type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide. J Immunol 125: 1104

    Google Scholar 

  19. Kaymakcalan Z, Spitalny GL, Bursuker I (1987) In vitro expression of secondary antitumor immunity by in vivo tumor-sensitized T cells: Inhibition by tumor-induced suppressor T cells. Cancer Immunol Immunother 25: 69

    Google Scholar 

  20. McKearn TJ (1980) Method for growing hybridomas in rats or mice. In: Kennett RH, McKearn TJ, Bechtol KB (eds) Hybridomas: a new dimension in biological analyses. Plenum Press, New York, p 403

    Google Scholar 

  21. Merluzzi VJ, Faanes RB, Choi YS (1980) Recovery of the capacity for cytotoxic T cell generation in cyclophosphamide-treated mice by the addition of Lyt-1+2− helper cells. Int J Immunopharmacol 2: 341

    Google Scholar 

  22. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 6: 409

    Google Scholar 

  23. Mokyr MB, Dray S (1983) Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res 43: 3112

    Google Scholar 

  24. Mokyr MB, Hengst JCD, Dray S (1982) Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. Cancer Res 42: 974

    Google Scholar 

  25. North RJ (1982) Cyclophosphamide-facilitated immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155: 1063

    Google Scholar 

  26. Peppoloni S, Mathieson BJ, Herberman RB, Overton RW, Gorelik E (1987) In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets. Cancer Immunol Immunother 24: 49

    Google Scholar 

  27. Rollinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H (1977) Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med 145: 455

    Google Scholar 

  28. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Special report: use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl J Med 319: 1676

    Google Scholar 

  29. Takei F, Levy JG, Kilburn DG (1976) In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice. J Immunol 116: 288

    Google Scholar 

  30. Taswell C (1981) Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 126: 1614

    Google Scholar 

  31. Yu S, Lannin DR, Tsui-Collins AL, McKhann CF (1980) Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas. Cancer Res 40: 2756

    Google Scholar 

  32. Zola H, Brooks D (1982) Techniques for the production and characterization of monoclonal hybridoma antibodies. In: Hurrell JGR (ed) Monoclonal hybridoma antibodies: techniques and applications. CRC Press, Boca Raton, p 1

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Microbiology and Immunology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA

    Shelley K. Hoover, Te-Chung Lee & Harry D. Bear

  2. Dept. of Surgery and Massey Cancer Center, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA

    Shelley K. Hoover, Sandra K. Barrett, Thomas M. T. Turk & Harry D. Bear

Authors
  1. Shelley K. Hoover
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra K. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas M. T. Turk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Te-Chung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Harry D. Bear
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by grants CA42443, CA48075 and T32-CA09210 from the National Cancer Institute, Department of Health and Human Services, and an American Cancer Society Clinical Oncology Career Development Award (H. D. Bear)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoover, S.K., Barrett, S.K., Turk, T.M.T. et al. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol Immunother 31, 121–127 (1990). https://doi.org/10.1007/BF01742376

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01742376

Keywords

Search

Navigation